| 规格: | 98% |
| 分子量: | 970.13 |
| 包装 | 价格(元) |
| 1mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
Background:
WKYMVM-NH2 TFA is a potent N-formyl peptide receptor (FPR1) and FPRL1/2 agonist, also activates several leukocyte effector functions such as chemotaxis, mobilization of complement receptor-3, and activation of the NADPH oxidase[1][2][3].
WKYMVM-NH2 TFA (10-1000 nM; 24 hours) induces Caco-2 cells proliferation[3].
WKYMVM-NH2 TFA (8 mg/kg; six times; for 5 days) ameliorates DSS-induced ulcerative colitis[3].WKYMVM-NH2 TFA affects cytokine (IL-17, IFN-γ, IL-6, IL-1β and TNF-α) profiles in the DSS colitis model[3].
[1]. Christophe T, et al. The synthetic peptide Trp-Lys-Tyr-Met-Val-Met-NH2 specifically activates neutrophils through FPRL1/lipoxin A4 receptors and is an agonist for the orphan monocyte-expressed chemoattractant receptor FPRL2. J Biol Chem. 2001 Jun 15;276(24):21585-93.
[2]. Christophe T, et al. Phagocyte activation by Trp-Lys-Tyr-Met-Val-Met, acting through FPRL1/LXA4R, is not affected by lipoxin A4. Scand J Immunol. 2002 Nov;56(5):470-6.
[3]. Sang Doo Kim, et al. The immune-stimulating peptide WKYMVm has therapeutic effects against ulcerative colitis. Exp Mol Med. 2013 Sep; 45(9): e40.
m.cnreagent.com